---
title: "Adial Pharmaceuticals | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296096907.md"
datetime: "2026-08-17T11:21:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296096907.md)
  - [en](https://longbridge.com/en/news/296096907.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296096907.md)
generator: "portal-rs"
---

# Adial Pharmaceuticals | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -11.25, missing the estimate of USD -0.91.

EBIT: As of FY2026 Q2, the actual value is USD -52.04 M.

The provided reference, a Form 8-K filing by Adial Pharmaceuticals, Inc., indicates that the company issued a press release on August 17, 2026, which included financial information for its quarter ended June 30, 2026. However, the actual financial and operational metrics, such as segment revenue, net income, gross margin, operating profit, operating margin, operating costs, cash flow, or unique company-specific indicators, are not detailed within this filing.

#### Outlook / Guidance

The reference does not contain any forward-looking statements or guidance regarding future financial performance or operational outlook for Adial Pharmaceuticals, Inc.

### Related Stocks

- [ADIL.US](https://longbridge.com/en/quote/ADIL.US.md)

## Related News & Research

- [Earth Science Tech (ETST) Taps into New Verticals with Zoolzy Acquisition](https://longbridge.com/en/news/297674876.md)
- [Faron Pharmaceuticals Ltd: Holding(s) In Company](https://longbridge.com/en/news/298025632.md)
- [TML Tender Offer - Publication of the Offer Document](https://longbridge.com/en/news/298070476.md)
- [Curanex Pharmaceuticals executes 1-for-20 reverse stock split](https://longbridge.com/en/news/298072376.md)
- [Pentwater Capital cuts Faron Pharmaceuticals stake below 3% via cash-settled swap](https://longbridge.com/en/news/298022326.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**